Oztan A, Fischer S, Schrock A B, Erlich R L, Lovly C M, Stephens P J, Ross J S, Miller V, Ali S M, Ou S-H I, Raez L E
Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA.
Providence Medical Institute, 2021 Santa Monica Blvd, Santa Monica, CA 90404, USA.
Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.
Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined. The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment. This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.
表皮生长因子受体（EGFR）突变是一部分肺癌的驱动因素。奥希替尼是一种第三代酪氨酸激酶抑制剂（TKI），最近被批准用于治疗T790M阳性非小细胞肺癌（NSCLC）；然而，对奥希替尼获得性耐药很明显，且耐药机制仍未完全明确。在两例接受奥希替尼治疗后病情进展的EGFR驱动的肺腺癌患者中，使用基于杂交捕获的综合基因组分析（CGP）和基于杂交捕获的循环肿瘤DNA（ctDNA）检测方法检测到了EGFR G724S突变。本研究证明了在疾病进展时基于组织和血液的杂交捕获基因组分析对于在临床上识别新的耐药机制的重要性。
